2020
DOI: 10.1016/j.ymben.2020.06.007
|View full text |Cite
|
Sign up to set email alerts
|

Metabolic engineering challenges of extending N-glycan pathways in Chinese hamster ovary cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 30 publications
0
8
0
Order By: Relevance
“…The overexpression of B3GNT2 and/or B4GALT1 is responsible for the elongation of glycans. Previously, overexpression of B4GALT1 was found to result in the elongation of glycans on CHO cells [31]. From the flow cytometry analysis, B4GALT1 appeared to be the limiting factor for the elongation of glycans in MDCK cells, while the elongation was limited by B3GNT2 in hCK cells.…”
Section: Discussionmentioning
confidence: 90%
See 2 more Smart Citations
“…The overexpression of B3GNT2 and/or B4GALT1 is responsible for the elongation of glycans. Previously, overexpression of B4GALT1 was found to result in the elongation of glycans on CHO cells [31]. From the flow cytometry analysis, B4GALT1 appeared to be the limiting factor for the elongation of glycans in MDCK cells, while the elongation was limited by B3GNT2 in hCK cells.…”
Section: Discussionmentioning
confidence: 90%
“…Recently, we and others have shown that poly-LacNAc containing N -glycans are critical for the binding of contemporary H3N2 viruses [8, 12]. Therefore, we used the glycosyltransferases B3GNT2 and B4GALT1 to increase the biosynthesis of LacNAc repeating units to produce extended N -glycans [12, 25, 26, 31]. We hypothesized that the overexpression of B3GNT2 and/or B4GALT1 in MDCK and hCK cells would produce appropriate glycan receptors for recent H3N2 (subclade 3C.2a) IAVs.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, the PTM pattern from CHO cells is not identical to human PTMs (Dumont et al, 2016) and the incompatibility with some types of proteins negatively affects drug efficacy, potency, or stability (Kuriakose et al 2016;Goh and Ng 2017). Therefore, besides further development of the CHO cell line to meet the high-quality PTM requirements and increased yields (Datta et al 2013;Koffas et al, 2018;Liang et al, 2020;Tejwani et al, 2018;Fouladiha et al, 2020;Wang et al, 2020), a lot of focus on improving hosts for biopharmaceutical production is on cell factories derived from human cells with the natural ability of generating human PTMs, such as the human embryonic kidney 293 (HEK293) cells (Almo and Love 2014;Malm et al, 2020;Tegel et al, 2020).…”
Section: Introductionmentioning
confidence: 99%
“…However, the PTM pattern of CHO cells is not identical to human PTMs (Dumont et al, 2016) and the incompatibility with some types of proteins negatively affects drug efficacy, potency or stability (Goh and Ng, 2017;Kuriakose et al, 2016). Therefore, besides further development of the CHO cell-line to meet the high-quality PTM requirements and increased yields (Datta et al, 2013;Fouladiha et al, 2020;Koffas et al, 2018;Liang et al, 2020;Tejwani et al, 2018;Wang et al, 2020), a lot of focus on improving hosts for biopharmaceutical production is on cell factories derived from human cells with the natural ability of generating human PTMs, such as the Human Embryonic Kidney 293 HEK293cells (Almo and Love, 2014;Malm et al, 2020;Tegel et al, 2020).…”
mentioning
confidence: 99%